Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw a large decline in short interest in July. As of July 15th, there was short interest totaling 20,246 shares, a decline of 87.2% from the June 30th total of 158,023 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 9,139 shares, the days-to-cover ratio is presently 2.2 days.

Institutional Trading of Ascentage Pharma Group International

A number of institutional investors have recently bought and sold shares of the business. UBS Group AG lifted its position in shares of Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares during the last quarter. Hsbc Holdings PLC purchased a new position in shares of Ascentage Pharma Group International during the second quarter worth approximately $391,000. Finally, Citadel Advisors LLC acquired a new position in Ascentage Pharma Group International in the third quarter valued at $383,000.

Analyst Ratings Changes

Several brokerages have recently issued reports on AAPG. BTIG Research reissued a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Monday, June 15th. Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. B. Riley Financial began coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. They set a “buy” rating and a $45.00 target price on the stock. China Intl Cap upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Ascentage Pharma Group International in a research report on Friday, April 24th. They issued a “buy” rating and a $40.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $46.43.

Ascentage Pharma Group International Price Performance

NASDAQ AAPG traded down $1.04 during trading hours on Friday, hitting $18.29. 4,578 shares of the company were exchanged, compared to its average volume of 16,572. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77. The company has a 50 day moving average of $18.56 and a two-hundred day moving average of $22.42. Ascentage Pharma Group International has a 52-week low of $16.36 and a 52-week high of $48.45.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.